切换至 "中华医学电子期刊资源库"
高级检索
中华危重症医学杂志(电子版)

中华危重症医学杂志(电子版) ›› 2017, Vol. 10 ›› Issue (04) : 252 -257. doi: 10.3877/cma.j.issn.1674-6880.2017.04.008

所属专题： 文献；

荟萃分析

左西孟旦对严重脓毒症/脓毒性休克患者病死率影响的Meta分析
周小洋1, 许兆军1,†(), 刘鹏1, 张玉楚1, 杨群1, 胡旭军1, 陈培服1   
  1. 1. 315000　浙江宁波，宁波市第二医院重症医学科
  • 收稿日期:2017-06-20 出版日期:2017-08-01
  • 通信作者: 许兆军
  • 基金资助:
    宁波市自然科学基金项目(2016A610139)

Effect of levosimendan on the overall mortality in patients with severe sepsis or septic shock: a meta-analysis

Xiaoyang Zhou1, Zhaojun Xu1,†(), Peng Liu1, Yuchu Zhang1, Qun Yang1, Xujun Hu1, Peifu Chen1   

  1. 1. Department of Critical Care Medicine, Ningbo No.2 Hospital, Ningbo 315000, China
  • Received:2017-06-20 Published:2017-08-01
  • Corresponding author: Zhaojun Xu
  • About author:
    Corresponding author: Xu Zhaojun, Email: guest666666@163.com
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

周小洋, 许兆军, 刘鹏, 张玉楚, 杨群, 胡旭军, 陈培服. 左西孟旦对严重脓毒症/脓毒性休克患者病死率影响的Meta分析[J]. 中华危重症医学杂志(电子版), 2017, 10(04): 252-257.

Xiaoyang Zhou, Zhaojun Xu, Peng Liu, Yuchu Zhang, Qun Yang, Xujun Hu, Peifu Chen. Effect of levosimendan on the overall mortality in patients with severe sepsis or septic shock: a meta-analysis[J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2017, 10(04): 252-257.

目的

系统评价左西孟旦对严重脓毒症或脓毒性休克患者病死率的影响。

方法

计算机检索PubMed、OVID、Cochrane临床试验数据库、万方数据库、中国知网数据库、维普网及中国生物医学文献数据库自建库至2016年12月期间关于左西孟旦治疗（实验组）与传统治疗（对照组）对成人严重脓毒症或脓毒性休克患者病死率影响的随机对照试验。由2名研究者按照纳入及排除标准独立进行文献筛选、提取和质量评估后，使用Stata/SE 11.0软件合并效应量行Meta分析，并绘制漏斗图检测发表偏倚。

结果

共纳入10篇符合入选标准的文献，共831例患者。Meta分析显示，与对照组比较，实验组对严重脓毒症或脓毒症休克患者的病死率并无明显下降[OR = 0.95，95%CI（0.71，1.27），Z = 0.36，P = 0.721]，漏斗图显示各研究间存在发表偏倚。同时，两组患者住ICU时长比较，差异亦无统计学意义[SMD = -0.24，95%CI（-0.56，0.07），Z = 1.51，P = 0.131]。

结论

左西孟旦不能降低严重脓毒症或脓毒性休克患者的病死率。

关键词: 左西孟旦, 脓毒症, 休克，脓毒性, 病死率, Meta分析
Objective

To assess the effect of levosimendan on the overall mortality in patients with severe sepsis or septic shock.

Methods

Randomized controlled trials focused on the effects of levosimendan treatment (experiment group) and traditional treatment (control group) on the overall mortality in adult patients with severe sepsis or septic shock were systematically retrieved from PubMed, OVID, Cochrane Library, Wanfang data, CNKI, VIP net and Chinese Biomedical Database from database inception to December 2016. Two reviewers independently screened articles according to the inclusion and exclusion criteria, extracted the data and evaluated the quality of the included studies. The mate-analysis was performed by Stata/SE 11.0 software, funnel plots were drawn to detect the publication bias.

Results

A total of 831 patients in 10 studies were included. Meta-analysis indicated that the overall mortality in the experiment group showed no significant difference as compared to the control group [OR = 0.95, 95%CI (0.71, 1.27), Z = 0.36, P = 0.721], the funnel plots demonstrated publication bias. Meanwhile, there was also no significant difference in the duration of intensive care unit stay between the two groups [SMD =-0.24, 95%CI (-0.56, 0.07), Z = 1.51, P = 0.131].

Conclusion

Levosimendan can't improve the overall mortality in patients with severe sepsis or septic shock.

Key words: Levosimendan, Sepsis, Shock, speptic, Mortality, Meta-analysis
表1 纳入文献的基本资料
纳入文献 样本量（例） 年龄[ ± s或M（P25，P75）] 性别[例（男/女）] APACHEⅡ评分[分， ± s或M（P25，P75）] Jadad评分（分）
实验组 对照组 实验组 对照组 实验组 对照组 实验组 对照组
Gordon等2016[7] 258 256 67（58，75） 69（58，77） 145/113 144/112 25（21，31） 25（21，30） 7
Meng等2016[8] 19 19 55 ± 18 50 ± 14 13/6 11/8 18.4 ± 4.5 19.5 ± 4.3 4
Torraco等2014[5] 13 13 70（58，80） 68（57，79） 11/2 8/5 - - 1
Memis等2012[11] 15 15 55 ± 19 56 ± 15 8/7 8/7 30.1 ± 7.6 27.0 ± 8.5 1
Morelli等2010[12] 20 20 68（55，74） 66（54，78） 14/6 13/7 - - 4
Morelli等2005[13] 15 15 61.5 ± 7.0 62 ± 7 11/4 12/3 24.4 ± 1.6 23.7 ± 2.1 3
黄河等2015[14] 26 25 66 ± 3 66 ± 5 15/11 15/10 23.7 ± 6.8 24.5 ± 6.9 1
方明星等2014[15] 18 18 61 ± 7 62 ± 7 14/4 13/5 23.5 ± 2.4 24.1 ± 2.1 3
刁井地等2014[16] 19 19 - - - - 19.6 ± 5.9 20.3 ± 4.8 1
赵湛元2013[17] 15 15 - - - - - - 1
图1 左西孟旦对严重脓毒症/脓毒性休克患者病死率影响的森林图
图2 左西孟旦对严重脓毒症/脓毒性休克患者住ICU时长影响的森林图
图3 左西孟旦对严重脓毒症/脓毒性休克患者病死率影响的Meta分析文献发表偏倚漏斗图
1
Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study[J]. Crit Care Med, 2006, 34 (2): 344-353.
2
Fernandes CJ Jr, Akamine N, Knobel E. Cardiac troponin: a new serum marker of myocardial injury in sepsis[J]. Intensive Care Med, 1999, 25 (10): 1165-1168.
3
Blanco J, Muriel-Bombin A, Sagredo V, et al. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicenter study[J]. Crit Care, 2008, 12 (6): R158.
4
中华医学会重症医学分会. 中国严重脓毒症/脓毒性休克治疗指南（2014）[J]. 中华内科杂志，2015，54(6):401-426.
5
Torraco A, Carrozzo R, Piemonte F, et al. Effects of levosimendan on mitochondrial function in patients with septic shock: a randomized trial[J]. Biochimie, 2014 (102): 166-173.
6
Zangrillo A, Putzu A, Monaco F, et al. Levosimendan reduces mortality in patients with severe sepsis and septic shock: a meta-analysis of randomized trials[J]. J Crit Care, 2015, 30 (5): 908-913.
7
Gordon AC, Perkins GD, Singer M, et al. Levosimendan for the prevention of acute organ dysfunction in sepsis[J]. N Engl J Med 2016, 375 (17): 1638-1648.
8
Meng JB, Hu MH, Lai ZZ, et al. Levosimendan versus dobutamine in myocardial injury patients with septic shock: a randomized controlled trial[J]. Med Sci Monit, 2016 (22): 1486-1496.
9
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample[J]. BMC Med Res Methodol, 2005 (5): 13.
10
Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions[M]. New York: John Wiley & Sons, 2008.
11
Memis D, Inal MT, Sut N, et al. The effects of levosimendan vs dobutamine added to dopamine on liver functions assessed with noninvasive liver function monitoring in patients with septic shock[J]. J Crit Care, 2012, 27 (3): 318.e1-e6.
12
Morelli A, Donati A, Ertmer C, et al. Levosimendan for resuscitating the microcirculation in patients with septic shock a randomized controlled study[J]. Crit Care, 2010, 14 (6): R232.
13
Morelli A, De Castro S, Teboul JL, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression[J]. Intensive Care Med, 2005, 31 (5): 638-644.
14
黄河，孙小聪，麦晓勤，等. 左西孟旦治疗脓毒症休克并心肌抑制的临床疗效观察[J]. 四川医学，2015，36(6):831-834.
15
方明星，董士民. 左西孟旦对脓毒性休克患者血流动力学及心功能的影响[J]. 中华危重病急救医学，2014，26(10):692-696.
16
刁井地，孙昭睿，马昭君，等. 左西孟旦在脓毒症休克心肌抑制患者中的应用研究[J]. 现代诊断与治疗，2014，25(24):5588-5589.
17
赵湛元. 左西孟旦对重症脓毒症患者组织氧耗及灌注影响的临床研究[J]. 中国医药指南，2013，11(31):323-324.
18
Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012[J]. Crit Care Med, 2013, 41 (2): 580-637.
19
Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care[J]. Crit Care Med, 2001, 29 (7): 1303-1310.
20
方俊君，章渭方. 脓毒症早期集束化治疗的研究进展[J/CD]. 中华危重症医学杂志（电子版），2014，7(6):374-376.
21
Lew WY, Yasuda S, Yuan T, et al. Endotoxin-induced cardiac depression in associated with decreased cardiac dihydropyridine receptor in rabbits[J]. J Mol Cell Cardiol, 1996, 28 (6): 1367-1371.
22
Hobai IA, Edgecomb J, LaBarge K, et al. Dysregulation of intracellular calcium transporters in animal models of sepsis induced cardiomyopathy[J]. Shock, 2015, 43 (1): 3-15.
23
Tavernier B, Mebazaa A, Mateo P, et al. Phosphorilation-dependent alteration in myofilament Ca2+ sensitivity but normal mytochondrial function in septic heart[J]. Am J Respir Crit Care Med, 2001, 163 (2): 362-367.
24
Sorsa T, Pollesello P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c[J]. Mol Cell Biochem, 2004, 266 (1-2): 87-107.
25
Sorsa T, Pollesello P, Rosevear PR, et al. Stereo-selective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization[J]. Eur J Pharmacol, 2004, 486 (1): 1-8.
26
Zager RA, Johnson AC, Lund S, et al. Levosimendan protects against experimental endotoxemic acute renal failure[J]. Am J Physiol Renal Physiol, 2006, 290 (6): F1453-F1462.
27
Erbuyun K, Vatansever S, Tok D, et al. Effects of levosimendan and dobutamine on experimental acute lung injury in rats[J]. Acta Histochem, 2009, 111 (5): 404-414.
28
Hasslacher J, Bijuklic K, Bertocchi C, et al. Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study[J]. Crit Care, 2011, 15 (4): R166.
[1] 张思平, 刘伟, 马鹏程. 全膝关节置换术后下肢轻度内翻对线对疗效的影响[J]. 中华关节外科杂志(电子版), 2023, 17(06): 808-817.
[2] 罗旺林, 杨传军, 许国星, 俞建国, 孙伟东, 颜文娟, 冯志. 开放性楔形胫骨高位截骨术不同植入材料的Meta分析[J]. 中华关节外科杂志(电子版), 2023, 17(06): 818-826.
[3] 马鹏程, 刘伟, 张思平. 股骨髋臼撞击综合征关节镜手术中闭合关节囊的疗效影响[J]. 中华关节外科杂志(电子版), 2023, 17(05): 653-662.
[4] 陈宏兴, 张立军, 张勇, 李虎, 周驰, 凡一诺. 膝骨关节炎关节镜清理术后中药外用疗效的Meta分析[J]. 中华关节外科杂志(电子版), 2023, 17(05): 663-672.
[5] 张晓燕, 肖东琼, 高沪, 陈琳, 唐发娟, 李熙鸿. 转录因子12过表达对脓毒症相关性脑病大鼠大脑皮质的保护作用及其机制[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 540-549.
[6] 姚咏明. 如何精准评估烧伤脓毒症患者免疫状态[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 552-552.
[7] 李雄雄, 周灿, 徐婷, 任予, 尚进. 初诊导管原位癌伴微浸润腋窝淋巴结转移率的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 466-474.
[8] 张再博, 王冰雨, 焦志凯, 檀碧波. 胃癌术后下肢深静脉血栓危险因素的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 475-480.
[9] 武慧铭, 郭仁凯, 李辉宇. 机器人辅助下经自然腔道取标本手术治疗结直肠癌安全性和有效性的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(05): 395-400.
[10] 莫闲, 杨闯. 肝硬化患者并发门静脉血栓危险因素的Meta分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 678-683.
[11] 刘佳铭, 孙晓容, 文健, 何晓丽, 任茂玲. 有氧运动对成人哮喘肺功能、生活质量以及哮喘控制影响的Meta分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 592-595.
[12] 段文忠, 白延霞, 徐文亭, 祁虹霞, 吕志坚. 七氟烷和丙泊酚在肝切除术中麻醉效果比较Meta分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 640-645.
[13] 杨海龙, 邓满军, 樊羿辰, 徐梦钰, 陈芳德, 吴威浩, 张生元. 腹腔镜胆总管探查术一期缝合术后胆漏危险因素Meta分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 545-550.
[14] 徐红莉, 杨钰琳, 薛清, 张茜, 马丽虹, 邱振刚. 体外冲击波治疗非特异性腰痛疗效的系统评价和Meta分析[J]. 中华老年骨科与康复电子杂志, 2023, 09(05): 307-314.
[15] 谭睿, 王晶, 於江泉, 郑瑞强. 脓毒症中高密度脂蛋白、载脂蛋白A-I和血清淀粉样蛋白A的作用研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(06): 749-753.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号